Download PDF
Dtsch Med Wochenschr 2022; 147(14): 931-938
DOI: 10.1055/a-1760-3843
Übersicht

Frühe Implementierung der „Fantastic four“ bei Herzinsuffizienz mit reduzierter Ejektionsfraktion

Leitliniengerechte medikamentöse Therapie – Ein praktischer LeitfadenA practical approach to guideline-directed pharmacological treatment for heart failure with reduced ejection fraction
Samira Soltani
,
Michael Böhm
,
Norbert Frey
,
Matthias Eden
,
Amr Abdin
,
Johann Bauersachs
› Further Information
Also available at
    Permissions and Reprints

Die aktuelle ESC-Leitlinie beinhaltet nicht nur neue medikamentöse Behandlungsmöglichkeiten, sondern auch die Etablierung der Therapie selbst. So wird eine möglichst frühzeitige Behandlung mit 4 die Prognose verbessernden Wirkstoffklassen bei Herzinsuffizienz-Patienten mit reduzierter Ejektionsfraktion empfohlen. Folgende Übersicht gibt einen praktischen Leitfaden zum sicheren und patientenorientierten Einsatz der Herzinsuffizienz-Medikation.

Abstract

The 2021 guidelines of the European Society of Cardiology for the diagnosis and treatment of heart failure recommend the early implementation of all four mortality-lowering drug classes for heart failure with reduced ejection fraction (HFrEF), i. e. angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor II blocker-neprilysin inhibitor (ARNI), betablocker (BB), mineralocorticoid receptor-antagonists (MRA), and sodium-glucose linked transporter-2 inhibitors (SGLT2i). This article aims to give a practical compendium supporting physicians to enable safe and efficacious treatment for patients with HFrEF.

Schlüsselwörter

Herzinsuffizienz - leitliniengerechte medikamentöse Therapie - HFrEF

Key words

heart failure - guideline-compliant drug therapy - HFrEF


Publication History

Article published online:
22 July 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 McDonagh TA, Metra M, Adamo M. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42: 3599-3726
    Search in Google Scholar
  • 2 Investigators*. Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure. New Engl J Medicine 1991; 325: 293-302
    CrossrefPubMedSearch in Google Scholar
  • 3 Wollert KC, Drexler H. Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Trial. Circulation 2002; 106: 2164-2166
    CrossrefPubMedSearch in Google Scholar
  • 4 McMurray JJV, Solomon SD, Inzucchi SE. et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New Engl J Med 2019; 381: 1995-2008
    CrossrefPubMedSearch in Google Scholar
  • 5 McMurray JJV, Packer M, Desai AS. et al. Angiotensin – Neprilysin Inhibition versus Enalapril in Heart Failure. New Engl J Med 2014; 371: 993-1004
    CrossrefPubMedSearch in Google Scholar
  • 6 Pitt B, Remme W, Zannad F. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New Engl J Med 2003; 348: 1309-1321
    CrossrefPubMedSearch in Google Scholar
  • 7 Packer M, Anker SD, Butler J. et al Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 2020; 383 (15) 1413-1424
    CrossrefPubMedSearch in Google Scholar
  • 8 Abdin A, Bauersachs J, Frey N. et al. Timely and individualized heart failure management: need for implementation into the new guidelines. Clin Res Cardiol 2021; 110: 1150-1158
    CrossrefPubMedSearch in Google Scholar
  • 9 Rosano GMC, Allen LA, Abdin A. et al. Drug Layering in Heart Failure: Phenotype-Guided Initiation. JACCHeart failure 2021; 9: 775-783
    CrossrefPubMedSearch in Google Scholar
  • 10 McMurray JJV, Packer M. How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction? A Redefinition of Evidence-Based Medicine. Circulation 2021; 143: 875-877
    CrossrefPubMedSearch in Google Scholar
  • 11 Bauersachs J. Heart failure drug treatment: the fantastic four. Eur Heart J 2021; 42: 681-683
    CrossrefPubMedSearch in Google Scholar
  • 12 Velazquez EJ, Morrow DA, DeVore AD. et al. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. New Engl J Med 2019; 380: 539-548
    CrossrefPubMedSearch in Google Scholar
  • 13 Vaduganathan M, Claggett BL, Jhund PS. et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet (London, England) 2020; 396: 121-128
    CrossrefPubMedSearch in Google Scholar
  • 14 Butler J, Anstrom KJ, Felker GM. et al. Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial. JAMA cardiology 2017; 2: 950-958
    CrossrefPubMedSearch in Google Scholar
  • 15 Pardo-Martínez P, Barge-Caballero E, Bouzas-Mosquera A. et al. Real world comparison of spironolactone and eplerenone in patients with heart failure. Eur J Intern Med 2022; 97: 86-94
    CrossrefPubMedSearch in Google Scholar
  • 16 Voors AA, Angermann CE, Teerlink JR. et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med 2022; 1-7
    CrossrefPubMedSearch in Google Scholar
  • 17 Bozkurt B, Coats AJS, Tsutsui H. et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. Eur J Heart Fail 2021; 23: 352-380
    CrossrefPubMedSearch in Google Scholar
  • 18 Halliday BP, Wassall R, Lota AS. et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet Lond Engl 2019; 393: 61-73
    CrossrefPubMedSearch in Google Scholar
  • 19 Marti CN, Fonarow GC, Anker SD. et al. Medication dosing for heart failure with reduced ejection fraction – opportunities and challenges. Eur J Heart Fail 2019; 21: 286-296
    CrossrefPubMedSearch in Google Scholar
  • 20 Swedberg K, Komajda M, Böhm M. et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875-885
    CrossrefPubMedSearch in Google Scholar
  • 21 Armstrong PW, Pieske B, Anstrom KJ. et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. New Engl J Med 2020; 382: 1883-1893
    CrossrefPubMedSearch in Google Scholar